Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles(Hospices Civils de Lyon), John F. Seymour(Peter MacCallum Cancer Centre), Fritz Offner(Ghent University Hospital), Armando López‐Guillermo(Hospital Clínic de Barcelona), David Belada(Charles University), Luc Xerri(Institut Paoli-Calmettes), Pierre Feugier(Université de Lorraine), Réda Bouabdallah(Institut Paoli-Calmettes), John Catalano(Frankston Hospital), Pauline Brice(Hôpital Saint-Louis), Dolores Caballero(Complejo Hospitalario de Salamanca), Corinne Haïoun(Hôpitaux Universitaires Henri-Mondor), Lars Møller Pedersen(Odense University Hospital), Alain Delmer(Université de Reims Champagne-Ardenne), David Simpson(North Shore Hospital), Sirpa Leppä(Helsinki University Hospital), Pierre Soubeyran(Institut Bergonié), Anton Hagenbeek(Amsterdam UMC Location University of Amsterdam), Olivier Casasnovas(CHU Dijon Bourgogne), Tanin Intragumtornchai(Chulalongkorn University), Christophe Fermé(Institut Gustave Roussy), María Gomes da Silva(Instituto Português de Oncologia Francisco Gentil), Catherine Sebban(Centre Léon Bérard), Andrew Lister(Queen Mary University of London), Jane Estell(Concord Hospital), Giuseppe Milone(Fundación para la Investigación, Docencia y Prevención del Cáncer), Anne Sonet(CHU Dinant Godinne UCL Namur), Myriam Mendila(Roche (Switzerland)), Bertrand Coiffier(Hospices Civils de Lyon), Hervé Tilly(Centre Henri Becquerel)
Cited by 1,063
Abstract
Related Papers
No related papers found
Powered by citation graph analysis